Immunotoxin fusion proteins and means for expression thereof

US8987426B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• Novartis AG · CH

Inventors

• David M. Neville, Jr. · Bethesda, US
• Jerry T. Thompson · Goose Creek, US
• Huaizhong Hu · Madison, US
• Jung-Hee Woo · Temple, US
• Shenglin Ma · Indianapolis, US
• Jonathan Mark Hexham · Dallas, US
• Mary Ellen Digan · Winchester, US

Key dates

• Filing date: Apr 10, 2012
• Grant date: Mar 24, 2015
• Expiry date: Apr 10, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.